Enzo Biochem's Q3 Revenues Rise 22 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday that its third-quarter revenues increased 22 percent, due in part to the firm's acquisitions of Biomol and Assay Designs over the past year.

The New York-based firm said that revenues for its Enzo Life Sciences segment increased 44 percent to $12.4 million from $8.6 million year over year. Products revenues for that segment jumped 50 percent to $10.5 million, due largely to the addition of revenues from Biomol and Assay Designs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.